Gout
Conditions
Interventions
A:Paeonia total glycosides capsule 0.6g Tid
C:Febuxostat capsules 20mg Qd + total glucosides of paeony capsules 0.6g tid
B:Blank control group
D:Febuxostat capsules 20mg Qd
Sponsors
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Department of Rheumatology and Immunology
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The age of 18-65 years old patients with autonomic activity ability, male patients; 2. The patients who met the diagnostic criteria of gout (American Society of Rheumatology, 1977); the number of gouty arthritis episodes >= 1 in recent half a year; 3. Patients with serum uric acid level >= 8.0 mg / dl (480 µ mol / L); 4. The patients voluntarily participated in the trial and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. The patients with acute gouty arthritis within one month before enrollment; patients with acute gouty arthritis more than 6 times or single attack duration >= 2 weeks in one year before enrollment; 2. Patients with active liver disease or abnormal liver function (ALT and AST are 2 times or more of the upper limit of normal value), and patients with impaired renal function (CR value exceeding the upper limit of normal value); 3. Subjects with white blood cell < 4.0 x 10^9 / L, anemia (hemoglobin less than 100g / L), platelet < 100 x 10^9 / L, or other blood system diseases; 4. Patients with serious heart, lung, central nervous system disease or malignant tumor; 5. Patients with mental illness or mental retardation who can not correctly describe their own feelings or cannot take medicine according to the doctor's advice; 6. Patients with hypertension and diabetes mellitus; 7. Patients with chronic diffuse connective tissue disease; 8. Patients with active peptic ulcer history in recent one year; 9. Patients with history of alcoholism, drug abuse or drug abuse in recent one year; 10. Patients who need to use the prohibited drugs prescribed in the protocol during the trial period; 11. Patients with allergic constitution or allergic to research drugs; 12. Patients in the control group were randomly assigned to other drugs such as norbutamol or norbutamol within 4 weeks; 13. Patients who participated in clinical trials of other drugs within 30 days before screening. 14. In addition to the above criteria, the investigator or Assistant Investigator determined that the patient was not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood uric acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood chemistry;Blood routine;Urine routine; | — |
Countries
China
Contacts
Public ContactJinhui Tao
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Outcome results
None listed